Voxelotor for Sickle Cell Disease Recalled After Safety Concerns
HCPLive
OCTOBER 1, 2024
Pfizer has announced the voluntary withdrawal of voxelotor in all markets after a report found the benefits do not outweigh the risks for sickle cell disease.
Sickle Cell Disease Related Topics 
Sickle Cell Disease Linked to Higher Risk of Retinal Vascular Occlusion
HCPLive
AUGUST 1, 2024
Patients with hemoglobin SS sickle cell disease type may experience a significantly elevated risk of retinal vascular occlusion.
Social Determinants of Health Shape Pain Outcomes in Sickle Cell Disease
HCPLive
OCTOBER 8, 2024
Education and employment, social and emotional functioning, and healthcare access are notable factors influencing pain in sickle cell disease.
Early sickle cell disease intervention may lower stroke risk
Medical Xpress - Cardiology
FEBRUARY 27, 2025
Bone marrow transplantation (BMT) can potentially cure sickle cell disease, an inherited and painful blood disorder, but because of its potential drawbacks and costs, patients and caregivers often face the difficult decision of whether to undergo the procedure.
AND017 Receives FDA Orphan Drug Designation for Sickle Cell Disease
HCPLive
OCTOBER 25, 2024
On October 25, 2024, Kind Pharmaceutical announced receipt of FDA Orphan Drug Designation for AND017 in the treatment of sickle cell disease.
Researchers identify safety of a potential new treatment to manage complications from sickle cell disease
Medical Xpress - Cardiology
APRIL 11, 2024
A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study published in Lancet Haematology.
Safety of a potential new treatment to manage complications from sickle cell disease
Science Daily - Heart Disease
APRIL 11, 2024
A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study.
Study Addresses Menstrual Pain in Sickle Cell Disease, Role of Reproductive Health Specialists
HCPLive
DECEMBER 10, 2023
Although more than half of female patients with sickle cell disease reported sickle cell pain associated with their menstrual cycles, only 12.5% had used ≥1 hormonal therapies within the past 3 months.
Hydroxyurea Therapy May Affect Fertility in Sickle Cell Disease
HCPLive
JUNE 13, 2024
Hydroxyurea treatment may impact seminal fluid levels and ovarian reserves in male and female patients with sickle cell disease.
Mortality in U.S. Youth; Gene Therapy for Sickle Cell Disease
Med Page Today
MAY 11, 2024
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.
Children with Sickle Cell Disease Experience Severe COVID-19 Infection
HCPLive
MARCH 13, 2024
In a registry-based analysis, more hospitalized children with SCD and COVID-19 had severe infection requiring supplemental oxygen, compared with the general population.
COVID-19 
115
115 
Elna Saah, MD: Unraveling the Current Landscape in Sickle Cell Disease
HCPLive
APRIL 18, 2024
Elna Saah, MD joins HCPLive to discuss the current landscape in sickle cell disease and recent advancements benefiting clinical care.
Sickle Cell Disease May Play Role in Childhood Lead Poisoning Cases
HCPLive
OCTOBER 2, 2024
An analysis of NYC’s lead registry data from 2005 to 2019 revealed a potential association between sickle cell disease and childhood lead poisoning.
Social Determinants of Health Impact Sickle Cell Disease Mortality in US
HCPLive
OCTOBER 3, 2024
An elevated social vulnerability index score was linked to increased mortality among patients with SCD in the 5-year CDC WONDER database.
Study Reveals Research Gaps on Acute Pancreatitis in Sickle Cell Disease
HCPLive
SEPTEMBER 8, 2024
A systematic review found a higher prevalence of acute pancreatitis in individuals with the HbSS genotype, though a meta-analysis could not be performed.
Disease Status Influences VTE Risk in Women with Sickle Cell Disease
HCPLive
AUGUST 11, 2024
Thrombotic risk is more likely influenced by disease status than hormonal contraception exposure in women with SCD.
Presence of CKD in Sickle Cell Disease Worsens In-Hospital Outcomes
HCPLive
MARCH 25, 2024
Chronic kidney disease was linked to increased mortality, higher costs, and the need for mechanical ventilation among hospitalized patients with sickle cell disease.
Updates, News in Sickle Cell Disease, with Steven Fein, MD
HCPLive
DECEMBER 17, 2024
Steven Fein, MD, discusses news and updates in sickle cell disease following ASH 2024.
CDC Opioid Guidelines Linked to Negative Consequences in Sickle Cell Disease
HCPLive
MARCH 12, 2024
The 2016 CDC guidelines led to significant decreases in opioid prescriptions and an increase in pain-related healthcare utilization for people with sickle cell disease.
Abnormal ECG Findings Prevalent Among People with Sickle Cell Disease
HCPLive
FEBRUARY 21, 2024
A meta-analysis revealed a higher prevalence of abnormal ECG findings in individuals with SCD compared to those without the disease.
Study Reveals Higher Prevalence of STIs Among Adolescents, Young Adults with Sickle Cell Disease
HCPLive
DECEMBER 11, 2023
A higher prevalence of STI diagnosis is observed in adolescents and young adults with sickle cell disease compared with controls.
Allogenic HSCT May Improve Sickle Cell Disease-Related Organ Dysfunction
HCPLive
MARCH 27, 2024
A new analysis summarized evidence on the effects of allogeneic HSCT on SCD-related organ dysfunction in pediatric and adult patients with SCD.
Stroke rates increasing in individuals living with SCD despite treatment guidelines
Science Daily - Heart Disease
SEPTEMBER 20, 2024
The incidence of stroke continues to increase for adults and children living with sickle cell disease (SCD) despite the Stroke Prevention Trial in Sickle Cell Anemia (STOP) establishing standards of care like transfusions and tests to measure blood flow in the brain for those deemed high-risk, according to a new study.
Clinical Pain Screening Proves Feasible in Pediatric Sickle Cell Disease
HCPLive
FEBRUARY 16, 2024
Over the study period, pain screening procedures were integrated within routine clinical visits and providers’ workflow in sickle cell disease care.
Pain Scores, Opioid Receipt Predict Hospitalization in Children with Sickle Cell Disease
HCPLive
DECEMBER 12, 2023
Final emergency department pain scores, opioid doses in the emergency department, and receipt of an opioid prescription at discharge predicted hospitalization and return visits.
Sickle Cell Disease with Venous Thromboembolism Linked to Higher Mortality
HCPLive
DECEMBER 12, 2023
Presented at ASH 2023, findings of a new study showed patients with sickle cell disease and venous thromboembolism have longitudinal worsening of left ventricular diastolic and right-sided cardiac function.
Hearing Loss Prevalence High in Children, Adults with Sickle Cell Disease
HCPLive
FEBRUARY 18, 2024
Hearing loss was more prevalent among children and adults with sickle cell disease and its traits compared to matched controls with normal hemoglobin.
Substance Use Disorder of Nitrous Oxide Uncommon in Sickle Cell Disease
HCPLive
MARCH 20, 2024
Results from the PHEDRE study show nitrous oxide in a gas mixture for pain was not problematic for most patients with sickle cell disease in France.
Children with Sickle Cell Disease Show No Alarming Trends After Opioid Use
HCPLive
FEBRUARY 19, 2024
No concerning patterns of long-term or increasing opioid use were observed within 3 years after first opioid prescription in opioid-naive children with SCD.
Patients with SCD Face Early Death Despite Improved Survival Rates
HCPLive
APRIL 15, 2024
A recent multi-center study identified risk factors linked to premature mortality in sickle cell disease, including male gender and hematologic and biochemical parameters.
Emergency Department Use for Sickle Cell Declined at Onset of COVID-19
HCPLive
AUGUST 6, 2024
Emergency department utilization patterns in people with sickle cell disease were impacted by the onset of the COVID-19 pandemic in 4 US states.
COVID-19 98
98 
Hydroxyurea Therapy Shown Not to Impact Onset of Puberty in Male Sickle Cell Disease Patients
HCPLive
DECEMBER 9, 2023
This new data on a European sickle cell disease cohort expands upon existing knowledge of the effects of HU on fertility, with the findings showing the benefits of cryopreservation.
Hematology Month in Review: March 2024
HCPLive
APRIL 3, 2024
Our March 2024 month-in-review in hematology features updates to the anemia pipeline, the latest research in sickle cell disease, and the role of SGLT2 inhibition on hematologic outcomes.
Stroke rates increasing in individuals living with sickle cell disease despite treatment guidelines: Study
Medical Xpress - Cardiology
SEPTEMBER 20, 2024
The incidence of stroke continues to increase for adults and children living with sickle cell disease (SCD), despite the Stroke Prevention Trial in Sickle Cell Anemia (STOP) establishing standards of care like transfusions and tests to measure blood flow in the brain for those deemed high-risk, according to a study published in Blood.
Frequent Hospitalized VOCs Worsens Mortality Risk in Sickle Cell Disease
HCPLive
APRIL 11, 2024
In a nationwide study of an adult SCD population, the risk of mortality increased with the number of HVOCs in the year before death.
Abstract TP147: Assessment of Inter-Rater Reliability of Fazekas Scoring on Magnetic Resonance Imaging in Patients With Sickle Cell Disease
Stroke Journal
FEBRUARY 1, 2024
Background:White matter disease is a common phenomenon in patients with sickle cell disease, that has been linked to cognitive impairment. However, there is no standardized approach for quantification of the cerebral disease burden. However, its utility in sickle cell disease has not yet been established.
RUBY: Reni-Cel Displays Promising Efficacy, Safety for Sickle Cell Disease
HCPLive
JUNE 14, 2024
Phase 1/2/3 trial data show the investigational gene-editing medicine has been well-tolerated, with encouraging efficacy, for people living with SCD.
Exa-Cel Shows Long-Term Clinical Benefit in Sickle Cell Disease, TDT
HCPLive
JUNE 17, 2024
The CRISPR-based gene therapy demonstrated durable effects on SCD and TDT, with the longest follow-up extending past 5 years.
Voxelotor Improves Cerebral Hemodynamic Parameters in Pediatric Sickle Cell Disease
HCPLive
FEBRUARY 20, 2024
Voxelotor decreases oxygen extraction fraction and cerebral blood flow towards levels observed in healthy children.
Voxelotor Benefits Red Blood Cell Functionality in Pediatric Sickle Cell Disease
HCPLive
FEBRUARY 26, 2024
An ancillary study of the phase 2 HOPE-KIDS 1 trial revealed voxelotor is associated with reduced sickling and hemolysis in children with SCD.
SGLT2is, GLP-1s Display Reno-Protective Benefit in Sickle Cell Disease
HCPLive
APRIL 28, 2024
Preliminary findings demonstrate an improvement in eGFR slope in nearly all patients with SCD after treatment with SGLT-2 inhibitors and GLP-1 receptor agonists.
Age, Genetics Help Predict Proliferative Sickle Cell Retinopathy
HCPLive
MAY 14, 2024
Age and sickle cell disease genotype predicted individuals with sickle cell retinopathy at risk for proliferative disease.
Dexamethasone Raises VTE Risk in COVID-19 Cases with Sickle Cell
HCPLive
DECEMBER 4, 2024
Dexamethasone treatment was linked to worse clinical outcomes in patients with sickle cell disease hospitalized for COVID-19.
COVID-19 59
59 
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
HCPLive
DECEMBER 8, 2024
Frangoul discussed highlights from the latest data update from the CLIMB SCD-121 trial of Casgevy.
Let's personalize your content